•  
  •  
 

Subject Area

Obstetrics and Gynecology

Article Type

Original Study

Abstract

Objectives This study aimed to demonstrate human equilibrative nucleoside transporter-1 (HENT1) gene expression patterns in acute myeloid leukemia (AML) patients and its role in disease progression. Background Cytarabine is the primary drug in different treatment schemas for AML and requires the HENT1 to enter cells. Patients and methods In this study, we analyzed HENT1 expression levels in 40 AML patients and 20 controls using the real-time quantitative reverse-transcriptase PCR. Results HENT1 was expressed in 42.5% of AML cases and 36% of controls. Our results showed a correlation between the HENT1 gene expression and the overall survival (OS), where HENT1-positive patients had a higher survival rate than HENT1-negative patients (P = 0.04). The results also showed a correlation between gene appearance and the response rate of treatment, as patients with positive HENT1 gene expression had a higher rate of complete recovery (58.8%) than the patients with negative HENT1 gene expression (30.4%). HENT1 expression was significantly correlated with OS and complete remission. Conclusion HENT1 gene expression is associated with better response to cytarabine treatment, with better OS in AML patients, both children and adults. HENT1 signaling may represent a novel therapeutic approach for the treatment of AML.

Download

Share

COinS